






TITLE OF CASE 





A previously well 54 year old lady (PT) presented with a short history of diplopia, cognitive decline, 
hallucinations and hypersomnolence. PT had progressive deterioration in short-term memory, 
ocular convergence spasm, tremor, myoclonus, gait apraxia, central pyrexia, dream enactment 
and seizures.  Results of investigations were normal including MRI brain, EEG, CSF (including 
CSF prion protein markers) and brain biopsy. PT died from pneumonia and pulmonary embolus. 
Brain post mortem analysis revealed neuropathological changes in keeping with Fatal Familial 
Insomnia (FFI); the diagnosis was confirmed on genetic testing. FFI is caused by an autosomal 
dominant and highly penetrant pathogenic Prion Protein gene PRNP. Although usually familial, 
Fatal Insomnia (FI) also occurs in a rare sporadic form (sFI). FI is a rare human prion disease with 
prominent sleep disturbance, autonomic, motor and cognitive and behavioural involvement. 




‘Fatal Insomnia; the elusive Prion disease’ illustrates a difficult case of a patient with the presenting 
features and natural history of a prion disorder, in the face of negative familiar investigations and 
newer highly sensitive and specific CSF methods. We aim to highlight that difficult and rare 
neurological cases may present acutely to hospital, sometimes via other specialties. The case is 
likely to resonate with BMJ readers as our initial ‘gut’ diagnosis proved correct despite off-putting 
investigation results. We discuss the epidemiology, clinical features, investigations, 
neuropathology, neurogenetics and supportive management of patients with Fatal Insomnia. 
CASE PRESENTATION 
A previously well 54 year old lady (PT) developed new onset diplopia followed by hearing 
impairment and ‘seashell’ tinnitus over several weeks. Four months following symptom onset, 
ophthalmic assessment found decompensated esophoria and ocular convergence spasm. Her 
family told the Ophthalmologist that she had been struggling with recent memory: her Acute Mental 
Test Score was reduced at 7/10. MRI brain with MR Angiography showed non-specific deep white 
matter changes in keeping with known vascular risk factors.  
A range of screening tests gave negative results (Table 1). PT’s tinnitus improved with the 
provision of hearing aids. However, two months later she was admitted to hospital with rapid 
cognitive decline, such that she had forgotten the names of her relatives. The family reported 




PT suffered from borderline Diabetes Mellitus and hypertension for which she took Amlodipine. 
She had undergone gastric banding or a balloon procedure in Spain many years previously, was 
an ex-smoker and did not drink alcohol. She was one of thirteen children, was separated from her 
partner and had five healthy children by two different partners. There was no neurological or 
otherwise relevant family history. 
 
On examination, PT had flattened affect, short term memory impairment, ocular convergence 
spasm, tremor, myoclonus and severe gait apraxia. At times she appeared to have hypnopompic 
hallucinations. There were no pyramidal, extrapyramidal or cerebellar signs. Addenbrooke’s 
cognitive assessment III (ACE) revealed a score of 34/100, deficient in all domains, particularly 
memory and verbal fluency. Her clinical state deteriorated rapidly; she had multiple fevers of 
central origin and developed clinically apparent sleep apnea (although this could not be confirmed 
formally as she removed pulse oximetry leads). PT had several probable seizures with eye rolling, 
unresponsiveness, posturing of the right arm and limb twitching. Her ACE score fell to 20/100 one 
month after admission to hospital.  
 
The results of in-hospital radiographic and specialist investigations are summarized in Table 2. 
 
INVESTIGATIONS If relevant 




Platelets      
CRP 
Urea & Electrolytes  
Liver function Tests  























Negative Antibody Screen 
Voltage-gated Potassium Channel Antibodies 
NMDA receptor Antibodies 
Anti-neuronal Antibodies 
IgLON5 Antibodies 
Anti-ganglioside (GQ1b) Antibodies 
Glycine Receptor Antibodies 
Glutamic Acid Decarboxylase (GAD) Antibodies 
Acetylcholine Receptor Antibodies 
TSH Receptor Antibodies 
Thyroid Peroxidase Antibodies 







Viral Hepatitis Screen 
CSF Examination 
Opening pressure 
Constituents- WCC, protein, RBC and glucose 
Microbiology, Culture and Staining 
Viral PCR  
Oligoclonal Bands 
S100 & 14-3-3 proteins 













Table 2: Summary of radiographic and specialist investigations performed during hospital 
admission. 
Imaging 
MRI Brain with Contrast & MR Angiogram 
 
Non-specific deep white matter vascular 
changes with a normal Circle of Willis. No 





CT Thorax, Abdomen & Pelvis Oesophageal thickening, but no evidence of 
overt malignancy 
Specialist Investigations 
Electroencephalography Intermittent sharp waves in the left 
centroparietal region but no periodic sharp 
wave complexes seen 
 
Repeat Electroencephalography Excess bilateral slow waves but no abnormality 
correlated with myoclonus 
Fluorescein Retinal Angiogram No evidence of retinal vasculitis 
Frontal Brain & Meninges Biopsy Normal Specimen. No evidence of prion protein, 
lymphoma or leptomeningeal vasculitis 
Oesophageal Duodenoscopy  
 





DIFFERENTIAL DIAGNOSIS  
We initially considered differential diagnoses of Creutzfeldt-Jakob disease, autoimmune 
encephalitis, intravascular lymphoma and dementia with Lewy Bodies (DLB). Serological tests of 
nutritional status were not performed, but in retrospect measures of Vitamin B1 for Wernicke’s 
Encephalopathy and Vitamin E for ataxia, would have been appropriate additions to our test 
battery, in view of the possibility of malnutrition linked to past bariatric surgery. 
 Given a positive DAT scan result (Figure 1) in the face of otherwise negative investigation 
including brain biopsy, atypical DLB was our working diagnosis.  
  
Subsequent post-mortem brain examination showed marked gliosis of the thalamic and inferior 
olivary nuclei (Figure 2, panel A and B). However, immunohistochemistry showed no evidence of 
any spongiform change or convincing prion protein (PrP) accumulation in the brain (Figure 2, panel 
C). Subsequent paraffin embedded tissue blot (PET blot) analysis undertaken by the National CJD 
Research & Surveillance Unit (NCJDRSU) in Edinburgh showed accumulation of the misfolded 
form of the prion protein (PrPSc) in the medial temporal lobe (Figure 2, panel D). Frontal Cortex 
(FC) and Cerebral Cortex (CC) samples were selected for biochemical analysis. The tissue 
samples were homogenised and precipitated with Sodium phosphotungstic acid (NaPTA) followed 
by proteolytic digestion with Proteinase K (PK) and high-sensitivity Western blotting.[1] Western 
blot analysis showed detectable levels of partially protease-resistant fragments in brain samples 
(FC and CC) using the monoclonal antibody 3F4, typed as “type 2B” (Figure 2, panel E). Genetic 
analysis revealed the D178N (aspartic acid to arginine) pathogenic variant in the PRNP gene 
[c.532G>A p.(Asp178Asn)], in combination with methionine homozygosity at codon 129 (MM) of 






Treatment with Rivastigmine for atypical DLB was unhelpful. No immunotherapy was tried on the 
basis that the aetiology was unknown but was presumed to be a neurodegenerative process. 
 Family members were subsequently offered counselling by our clinical genetics team.  
 
OUTCOME AND FOLLOW-UP 
PT was discharged to a nursing home but readmitted forty-eight hours later with hospital-acquired 







Fatal Insomnia (FI) is a rare human prion disease, which occurs in both sporadic (sFI) and familial 
forms (FFI). It typically presents with prominent sleep disturbance, and is usually inherited.[2]  
As a group, the transmissible spongiform encephalopathies –prionopathies or prion diseases - occur 
in sporadic, inherited and acquired forms.  All involve the accumulation of an aggregated and partially 
protease-resistant form (PrPSc) of the prion protein (PrP) with the capacity to drive the further 
conversion of normal PrP molecules (PrPc) into the misfolded, protease resistant and disease 
associated isoform.[2]  Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common human prion 
disease, with a world-wide incidence of around 1-2 cases per million population/year.  
FI is much rarer: only 70 known affected kindreds and 25 typical cases of sFI have been reported 
world-wide.[2] Age of onset in FFI varies between 36-72 years affecting males and females equally.  
sFI has been reported in a handful of cases with similar clinical and neuropathological features to 
the familial phenotype.[3] The clinical features of FI involve sleep, autonomic, motor, behavioural 
and cognitive disturbance. However, although titled ‘Fatal Insomnia’, insomnia is not a defining 
feature of the disease. Involvement of the thalamus, hypothalamus and higher brainstem can affect 
sleep in a variety of ways. Insomnia is the most frequently observed sleep disturbance, but REM 
sleep behaviour disorder and dream enactment may also be seen. Early clinical manifestations 
include altered vigilance, fluctuating diplopia, disrupted circadian rhythm, apathy and executive 
dysfunction. Nocturnal sleep disturbance can lead to daytime somnolence. Autonomic features may 
then ensue with hypertension, evening pyrexia, perspiration, lacrimation, salivation and impotence. 
Gait apraxia, ataxia, myoclonus and other motor signs (Table 3) may emerge as the disease 
progresses. Occasional convulsive seizures have been reported.[3] Patients may die as a result of 
secondary pneumonia.[3] 
  
Other forms of human Prion disease, atypical Parkinsonism, Dementia with Lewy Body disease, 
Autoimmune Encephalitis and Intravascular Lymphoma should all be considered when investigating 
for FI.[1] 
 
As this case illustrates, standard investigations in life may be normal. The following investigations 
may assist in the suspected diagnosis of FI; MRI of the brain may show non-specific changes of 
cortical, cerebral and cerebellar atrophy.[2,3]  Cortical ribboning seen in sCJD and diffusion 
restriction changes on diffusion-weighted MRI brain, are not seen in FI.[2] Periodic complexes on an 
 
 
EEG of the kind seen in CJD, are not typically present but may develop in patients with a long 
duration of illness. Abnormality of Cerebrospinal fluid (CSF) 14-3-3 protein occurs in only 50% 
patients with FI.[2] CSF RT Quic is positive in 83% of FFI cases but only in 50% of sFI patients. PET 
Fluorodeoxyglucose has shown hypometabolism in the thalamus, basal ganglia and limbic system 
in some cases.[2,3] 
 
Polysomnography may show disruption of the sleep wake cycle,[2] with sleep state dissociation (loss 
of the normal boundaries between non-REM sleep, REM sleep and wakefulness). Total duration of 
sleep is often reduced and slow wave sleep may be lost entirely. Hypercortisolaemia and low 
melatonin levels have been reported.[3,4]  
 
Fatal Insomnia is caused by the highly penetrant, autosomal dominant, pathogenic Prion Protein 
gene (PRNP) variant c.532G>A p.(Asp178Asn) on chromosome 20, previously called the D178N 
mutation.[5] The codon 129 variant on the same allele modifies the phenotype expressed at codon 
178; with p.Met129 the phenotype is usually FI whereas with p.Val129 it is usually typical CJD.[5] 
 
Neuropathological assessment at post mortem remains the definitive means of confirming a 
diagnosis of FI. Neuropathological changes in FI include prominent thalamic,[4] and inferior olivary 
neuronal loss and astrogliosis.[2] Cortical and subcortical gliosis may be seen to a milder degree as 
well as spongiform degeneration later in the course of disease, with more extensive changes 
observed as the disease progresses. PET blot analysis may be useful in the detection PrPSc  when 
standard immunohistochemical methods fail to detect evidence of the prion protein.[6] 
 
The management of FI is currently supportive, with genetic counselling for at risk family members.  
 
Table 3: Phenotypic Features of Fatal Insomnia 
Sleep & behavioural 
 Insomnia 
 Sleep state dissociation with dream enactment 
 Altered vigilance 








 Pyramidal signs  
 Positive Babinski reflex 
 Gait apraxia 
Dysautonomia 
 Hypertension 







We initially suspected a diagnosis of a prion disease in this case of rapidly progressive dementia 
with prominent somnolence, gait apraxia and myoclonus. We were discouraged from the diagnosis 
by negative investigations including CSF examination and brain biopsy. Formal polysomnography 
might have suggested the diagnosis, but was difficult to perform in this agitated patient. A 
neuropathological post-mortem of PT’s brain eventually provided the crucial clue to the correct 
diagnosis, of FFI, with confirmation by further specialised neuropathological and genetic 
assessment by the NCJDRSU. We have since offered genetic counselling to at risk family 
 
 
members. For those wishing to learn more of the human dimension of FFI, a moving documentary, 
Dying to Sleep, is available at https://www.youtube.com/watch?v=AxjNay_TRRg 
 
 
LEARNING POINTS/TAKE HOME MESSAGES 3-5 bullet points 
 Fatal Insomnia is a rare prion disease with prominent sleep disturbance, cognitive, 
autonomic, motor and behavioural involvement.  
 Fatal Familial insomnia is highly penetrant and arises from the Prion Protein gene (PRNP) 
variant c.532G>A p.(Asp178Asn) on chromosome 20, previously called the D178N 
mutation. 
 Sporadic Fatal Insomnia has similar clinical and neuropathological features to Fatal 
Familial Insomnia.[7] 
 Standard screening tests for investigating human prion disease such as MRI brain, EEG 
and CSF can be normal. Polysomnography and FDG PET may support a diagnosis of FI 
but genetic and neuropathological assessment remains key to confirming the diagnosis. 
 Management is best supportive care but early suspicion allows timely planning for the 
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Figure 2: Neuropathological analysis, undertaken at the National Creutzfeldt-Jakob Disease Research 
and Surveillance Unit (NCJDRSU). Routine histological assessment using a haematoxylin and eosin 
(H&E) stain showed striking thalamic gliosis (a; x10 magnification) confirmed by immunohistochemical 
assessment of glial fibrillary acidic protein (GFAP) expression (b; x10 magnification). 
Immunohistochemical assessment of abnormal prion protein expression was assessed using a number 
of antibodies but was mostly negative (c; 12F10 x10 magnification) and only focal weak expression. 
However, the paraffin-embedded tissue (PET) blot technique clearly demonstrated abnormal prion 
protein (d). Western blot analysis of PrPSc in Fatal Familial Insomnia, codon 129MM, type 2B (FFI), 
compared with sporadic CJD MM1 (sCJDMM1), type 1A; sporadic CJD MM2 (sCJDMM2), type 2A; 
and variant CJD MM (vCJD), type 2B. For the FFI case, PrPSc analysis of Frontal Cortex (FC) and 
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EXAMPLE OF A WELL PRESENTED CASE REPORT 
Resection of a large carotid paraganglioma in Carney-Stratakis syndrome: a multidisciplinary feat 
 
